H
Hendrik Schmidt
Researcher at Boehringer Ingelheim
Publications - 41
Citations - 1371
Hendrik Schmidt is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Respimat & Asthma. The author has an hindex of 13, co-authored 41 publications receiving 1238 citations.
Papers
More filters
Journal ArticleDOI
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier,Bettina Hederer,Thomas Glaab,Hendrik Schmidt,Maureen P.M.H. Rutten-van Mölken,Kai M. Beeh,Klaus F. Rabe,Leonardo M. Fabbri +7 more
TL;DR: Results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations.
Journal ArticleDOI
Design of the PF-ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
Kevin R. Flaherty,Kevin K. Brown,Athol U. Wells,Emmanuelle Clerisme-Beaty,Harold R. Collard,Vincent Cottin,Anand Devaraj,Yoshikazu Inoue,Florence Le Maulf,Luca Richeldi,Hendrik Schmidt,Simon L.F. Walsh,William Mezzanotte,Rozsa Schlenker-Herceg +13 more
TL;DR: The main secondary endpoints are the absolute change from baseline in King’s Brief Interstitial Lung Disease Questionnaire total score, time to first acute interstitial lung disease exacerbation or death and time to all-cause mortality over 52 weeks.
Journal ArticleDOI
Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status
Huib A. M. Kerstjens,Petra Moroni-Zentgraf,Donald P. Tashkin,Ronald Dahl,Pierluigi Paggiaro,Mark Vandewalker,Hendrik Schmidt,Michael Engel,Eric D. Bateman +8 more
TL;DR: Once-daily tiotropium 5 μg compared with placebo improved lung function, reduced the risk of asthma exacerbations and asthma worsening, and improved asthma symptom control, independent of a broad range of baseline characteristics, as add-on to ICS plus LABAs in patients with severe symptomatic asthma.
Journal ArticleDOI
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
Kai M. Beeh,Thomas Glaab,Susanne Stowasser,Hendrik Schmidt,Leonardo M. Fabbri,Klaus F. Rabe,Claus Vogelmeier +6 more
TL;DR: The frequent exacerbator phenotype was closely associated with exacerbation-related hospitalisations, and exacerbations were associated with poorer survival, which was associated with three-fold increase in mortality.
Journal Article
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Oliver Distler,Kevin K. Brown,Jörg H W Distler,Shervin Assassi,Toby M. Maher,Vincent Cottin,John Varga,Carl Coeck,Martina Gahlemann,Wiebke Sauter,Hendrik Schmidt,Kristin B. Highland,Senscis trial investigators +12 more
TL;DR: The SENSCIS™ trial is a randomised, placebo-controlled Phase III trial that will evaluate the efficacy and safety of nintedanib in patients with SSc-ILD, and the annual rate of decline in FVC assessed over 52 weeks.